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Abstracts
 
SION:
 
 We demonstrated gender and ethnic differences
and temporal trends in avoidable hospitalization. Avoid-
able hospitalization is a sensitive tool for monitoring ac-
cess to and adequacy of primary ambulatory care.
 
MD2
MEASURING REDUCED PRODUCTIVITY 
DURING PAID LABOR
Rothermich EA1, Pathak DS2
1The Lewin Group, San Francisco, CA, USA; 2The Ohio State 
University, Columbus, OH, USA
OBJECTIVE: A new method for measuring reduced pro-
ductivity during paid labor has been proposed in the
Health and Labor Questionnaire (HLQ). How this method
relates to the more common impairment approach is un-
known. Therefore, the objective of this study was to
compare the two methods of measurement. METHODS:
A face-to-face interview questionnaire with items on re-
duced productivity during paid labor was developed and
pilot-tested. The final interview was administered to a
convenience sample of 102 informal caregivers of the eld-
erly in an observational panel study with two survey
waves. Employed caregivers were asked to estimate the
extent to which their productivity while at work during
the previous two weeks was reduced by their caregiving
activities, using both the HLQ approach and an impair-
ment approach. In the HLQ approach, respondents esti-
mated the amount of time necessary to compensate for
their reduced productivity. In the impairment approach,
respondents rated their impairment on a scale from 0 to
10. Then, the impairment rating was converted to an
hourly value. Paired t-tests were conducted to examine
the differences between the HLQ approach and the im-
pairment approach. RESULTS: In the first survey wave,
53 employed caregivers reported an average of 9.0 hours
of reduced productivity using the impairment approach
compared to 3.5 hours using the HLQ approach. This
difference was statistically significant (P  0.01). In the
second survey wave, 54 employed caregivers reported an
average of 8.7 hours of reduced productivity using the
impairment approach compared to 4.0 hours using the
HLQ approach. Again, the difference was statistically
significant (P  0.01). CONCLUSIONS: The approach
used to measure reduced productivity during paid labor
influences the results obtained. Estimates of reduced pro-
ductivity during paid labor are greater when the impair-
ment measurement approach is used than when the HLQ
approach to measurement is used.
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OBJECTIVE: Measure the benefits of delaying the pro-
gression to blindness and compute an overall index that
summarizes the benefits to patients treated for eye prob-
lems. METHODS: Patient benefits are measured in terms
of the reduction in symptoms and disabilities, and in
terms of the patient’s ability to perform preferred activi-
ties in their daily living. The index is based on earlier
work in the field of index theory, distance functions, and
production economics. It uses both clinical outcome data
and data on specific daily life activities. The index results
in a single measure of relative changes in functional abil-
ity, for each individual. Daily life activities are treated as
outputs that the individual is able to perform. Resources
that the individual uses to achieve the outputs are treated
as inputs. Hence, treatment may increase the input level
of a particular individual and by that increase the output
possibility set, and subsequently the individual’s choice
between different output combinations. The situation be-
fore treatment is compared with the situation after treat-
ment. The index numbers are calculated from the Swed-
ish Cataract Register, and from clinical trial data. Cost
data are collected from the literature. RESULTS: The
suggested index approach successfully connects multidi-
mensional outcome data with daily life activities, without
being dependent on an a priori set of weights or second-
ary statistical analysis. The index allows different vari-
ables to be measured in different units without affecting
the resulting index number. The preliminary empirical re-
sults indicate that new technology and proper timing of
the medical intervention is crucial for the economic justi-
fication of the intervention. CONCLUSION: With a
minimum of assumptions the suggested index makes it
possible to analyze a medical intervention using all of the
appropriate variables. The index may prove particular
useful in the decision process of medical interventions
and when balancing costs and benefits.
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SCREENING FOR LEFT VENTRICULAR 
SYSTOLIC DYSFUNCTION (LVSD)
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OBJECTIVE: To estimate the cost-effectiveness of
screening for LVSD in patients with cerebro-vascular ac-
cident (CVA), peripheral vascular disease (PVD) or tran-
sient ischaemic attack (TIA) versus age matched controls.
METHODS: Results of electrocardiography (ECG) or
measurement of brain natriuretic peptide (BNP) were
compared with echocardiography (LVSD  ejection frac-
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tion 40). Cost-effectiveness of ACE inhibitor (ACE-I)
treatment of LVSD was estimated from 12 published
studies. RESULTS: We investigated 257 cases with CVA,
PVD or TIA and 199 controls. The overall prevalence of
LVSD was 28% in the cases and 6% in the controls. Past
history of MI was associated with a high risk of LVSD in
both cases (48%) and controls (33%) (Relative Risk
1.53, 95% CI 0.87–2.71). However, 21% of cases with
no past history of MI had LVSD in comparison with 1%
of the controls (Relative Risk 17.51, 95% CI 4.29–
71.40). Measurement of BNP cost more than ECG screen-
ing, was less sensitive and specific and consequently not
as cost-effective. Echoing only those patients with history
of MI was the most cost-effective strategy in cases and
controls (cost per LVSD detected $786 and $1,203). The
cost per additional LVSD detected by ECG screening of
patients with no MI was $1,392 in cases vs $22,304 in
controls. The cost per additional LVSD detected by echo-
ing all subjects was $3,349 for cases vs $40,488 for con-
trols. Screening and treating LVSD with ACE-I was cost-
effective ($50,000 per Life Year Saved) for all case
patients or for controls with a history of MI, but not for
controls with no history of MI ($134,963–$312,623 per
LYS). CONCLUSIONS: Screening patients with non-car-
diac vascular disease for LVSD is almost as cost-effective
as screening patients with a past history of MI. Both
strategies compare favorably with other interventions for
cardiovascular disease.
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Annemans L1, Robays H2, Rasmussen JA3, Lewis DN4, 
Kestens D5, Gilles B5
1VUB-HEDM, Meise, Belgium; 2RUG, Gent, Belgium; 3Leo 
Pharmaceutical Products, Ballerup, Denmark; 4NERA, London, 
UK; 5Leo Pharma, Zaventem, Belgium
OBJECTIVES: In acute sub-massive pulmonary embo-
lism (PE), Low Molecular Weight Heparins (LMWH) are
as effective as IV unfractionated heparin (UFH), but eas-
ier to administer with a slightly better adverse events pro-
file. In order to assess the health economic consequences
of LMWH, we examined the cost of using the LMWH
tinzaparin instead of UFH in the treatment of acute sub-
massive PE in Belgium, from a hospital perspective.
METHODS: The evaluation is based on a clinical trial
involving 612 patients (Simonneau et al, NEJM, 97), re-
porting differences in the adverse outcomes of both treat-
ments. In order to represent actual clinical practice in
Belgium, a 2-round Delphi-panel was conducted in which
clinicians produced data about average treatment pat-
terns. A patient record review looking at actual clinical
treatment of 54 patients with PE in five Belgian hospitals
was used to validate the findings from the panel. Initial
treatment costs that differed between the two strategies
and costs of adverse outcomes reported in the trial were
considered, since other costs (e.g. diagnosis) are the same
for both options. Drug costs were obtained from list
prices, and staff costs and material costs were provided
by University Hospital Gent. RESULTS: Even though
treating PE with tinzaparin increases drug costs, the total
cost of treating a patient is less than treatment with UFH:
Bef 4,817 (119.4 Euro) for UFH vs. Bef 3,837 (95.1
Euro) for tinzaparin. Tinzaparin removes the need for
aPTT tests, and produces savings on staff time, material
usage, and treating adverse events. The results are robust
both to the plausible range of uncertainty in the results of
the clinical trial and to broad changes in the medical re-
source use data. CONCLUSIONS: Overall, tinzaparin re-
duces costs through greater ease of administration, sav-
ing staff time and material costs, and by removing the
need for laboratory monitoring.
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Dyslipidemia is an established risk factor for coronary
heart disease (CHD). Primary and secondary prevention
of dyslipidemia decreases CHD morbidity and mortality.
Compliance and persistence with HMG CoA reductase
inhibitor (“statin”) therapy has been sporadic, despite
the lipid lowering ability of these drugs. OBJECTIVES:
The purpose of this study was to determine if a struc-
tured, educational, pharmacist-directed intervention pro-
gram would influence the outcomes of dyslipidemia therapy.
METHODS: This study utilized a stratified, randomized,
open-label, fifty site multi-center comparison of a com-
munity pharmacy-based health education and medication
management program for dyslipidemia patients. Experi-
mental group patients received a structured, pharmacist
directed series of interventions and monthly lipid panel
measurements. Control patients received the traditional
standard of pharmacy care. Statistical analyses included
t-test examination of differences in mean values for lipid
panel measurements between groups. RESULTS: A ma-
jority of patients at baseline had CHD (57%) and 32%
of patients had 2 risk factors as indicated by National
Cholesterol Education Panel (NCEP) guidelines. Baseline
mean low-density lipoprotein (LDL) levels in the inter-
vention group and non-intervention group were 142 mg/
dl and 140 mg/dl respectively, indicating a majority of
moderate to high-risk patients was not at NCEP goal.
Findings to date do show improvements in total choles-
terol and LDL reduction after the pharmacist interven-
tion as compared to the non-intervention group, P 
0.001. Additionally, intervention patients reported im-
provements in the medication persistence survey scores.
